The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: A study in 39 cases of MDS or AML

Leukemia

Volumn 25, Issue 5, 2011, Pages 874-877

  Haferlach, C ^a   Bacher, U ^b   Haferlach, T ^a   Dicker, F ^a   Alpermann, T ^a   Kern, W ^a   Schnittger, S ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; NEUROFIBROMIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CANCER GROWTH; CELL COUNT; CHROMOSOME; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; HUMAN; LETTER; LEUKEMOGENESIS; MALE; MYELODYSPLASTIC SYNDROME; ONCOGENE N RAS; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 3; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; GENES, RAS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUROFIBROMIN 1; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 79955814184     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.5     Document Type: Letter

References (8)

1. Swerdlow S, Campo E, Lee Harris N, Jaffe E, Pileri S, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, 4th edn. IARC press: Lyon.
2. Gröschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010; 28: 2101-2107.
3. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003; 101: 837-845. (Pubitemid 36139348)
4. Grimwade D, Hills R, Moorman AV, Walker H, Chatters S, Goldstone A et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood 2010; 116: 354-365.
5. Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, Van Zelderen-Bhola SL et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 20: 3890-3898.
6. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853. (Pubitemid 43726786)
7. Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W et al. AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24: 1065-1069.
8. Weisser M, Haferlach C, Haferlach T, Schnittger S. Advanced age and high initial WBC influence the outcome of inv(3)(q21q26)/ t(3;3)(q21;q26) positive AML. Leuk Lymphoma 2007; 48: 2145-2151. (Pubitemid 350107691)